Sabby Management’s Ascendis Pharma A/S ASND Stock Holding History

Sabby Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-160,000	Closed	-$2.81M	–	385
2015 Q2	$2.81M	Sell	160,000 -34,023	-18%	-$595K	0.1%	135
2015 Q1	$3.37M	Buy	+194,023	New	+$3.53M	0.14%	107

Other funds holding ASND

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Sabby Management's ASND Position: Q3 2015 in Review

Sabby Management sold out of Ascendis Pharma A/S (ASND) in Q3 2015, closing a stake of 160,000 shares — an estimated $2.81M sold.

Sabby Management first reported a position in ASND in Q1 2015 and held it in 2 quarters. The position peaked at $3.37M in Q1 2015. 26 funds tracked by Wall St. Rank hold ASND as of Q3 2015.

Sabby Management reported no remaining Ascendis Pharma A/S position as of Q3 2015 after selling out during the quarter.
Sabby Management sold 160,000 Ascendis Pharma A/S shares in Q3 2015, an estimated $2.81M.
Sabby Management first reported a position in Ascendis Pharma A/S in Q1 2015 and held it in 2 quarters.
Sabby Management's Ascendis Pharma A/S position peaked at $3.37M in Q1 2015.
26 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2015.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.